EMA Considers Adolescent Booster-Dose Application for Comirnaty
EMA has started its evaluation of an application for the use of a booster dose of Comirnaty in adolescents aged 12–15 years.
The European Medicines Agency (EMA) has started its evaluation of an application for the use of a booster dose of BioNTech/Pfizer’s COVID-19 vaccine, Comirnaty, in adolescents aged 12–15 years.
As reported in a Feb. 8, 2022 press release, EMA’s Committee for Medicinal Products for Human Use (CHMP) will perform an accelerated assessment of data that has been submitted by the company responsible for marketing Comirnaty. The data that has been submitted includes real-world evidence from Israel.
Currently, the booster doses of Comirnaty are approved to be administered in patients aged 18 years and older. An application for a booster dose of the vaccines in patients aged 16–17 years is also ongoing.
EMA will provide further information and updates on the evaluation in due course.
Source: EMA
EMA Recommends Imfinzi-Based Perioperative Regimen for Treating Resectable NSCLC
March 10th 2025The committee’s recommendation is based on results from a Phase III trial in which Imfinzi demonstrated a reduced risk of recurrence, progression, or death by 32% compared to neoadjuvant chemotherapy alone.
International Women’s Day 2025: A Promising Future for Gender Diversity in Pharma
March 8th 2025In an interview with BioPharm International®, Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
